array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Novartis Gene Therapies, Inc."
["slug"]=>
string(19) "a26d9-us-avexis-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c"
["description"]=>
string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP"
["address_street"]=>
string(24) "2275 Half Day Rd Ste 200"
["address_place"]=>
string(11) "Bannockburn"
["address_region"]=>
string(8) "Illinois"
["founding_date"]=>
string(10) "2010-02-28"
["website_domain"]=>
string(12) "novartis.com"
["website_url"]=>
string(24) "https://www.novartis.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(219)
["article_count"]=>
int(7769)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(36) "When will Sandoz shares turbocharge?"
["snippet_en"]=>
string(107) "Sandoz shares have not moved since the beginning of the year. According to analysts, they should be higher."
["url"]=>
string(83) "https://www.cash.ch/news/top-news/wann-zundet-die-aktie-von-sandoz-den-turbo-702874"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/e3ad7768-be6e-4e20-9975-496907bcea00"
["source"]=>
string(7) "cash.ch"
["publication_date"]=>
string(10) "2024-04-17"
["categories"]=>
array(4) {
[0]=>
string(14) "Issuing Shares"
[1]=>
string(12) "Stock Market"
[2]=>
string(16) "Share Repurchase"
[3]=>
string(8) "spin-off"
}
}
[1]=>
array(7) {
["title_en"]=>
string(84) "Acromegaly Market Analysis: Uncovering Insights and Trends in Global Market Industry"
["snippet_en"]=>
string(84) "Acromegaly Market Analysis: Uncovering Insights and Trends in Global Market Industry"
["url"]=>
string(142) "https://industrytoday.co.uk/market-research-industry-today/acromegaly-market-analysis-uncovering-insights-and-trends-in-global-market-industry"
["image_url"]=>
NULL
["source"]=>
string(19) "industrytoday.co.uk"
["publication_date"]=>
string(10) "2024-04-15"
["categories"]=>
array(1) {
[0]=>
string(15) "Market Movement"
}
}
[2]=>
array(7) {
["title_en"]=>
string(70) "EC Approves Illumina’s Plan to Divest Cancer Diagnostics Maker Grail"
["snippet_en"]=>
string(101) "[ April 13, 2024] Vertex’ s$ 4.9B bet; Layoffs at Novartis, Genentech, Sanofi; Star founders unveil"
["url"]=>
string(119) "https://sdbn.org/san-diego-biotech-news/2024/04/12/ec-approves-illuminas-plan-to-divest-cancer-diagnostics-maker-grail/"
["image_url"]=>
NULL
["source"]=>
string(8) "sdbn.org"
["publication_date"]=>
string(10) "2024-04-13"
["categories"]=>
array(1) {
[0]=>
string(7) "Layoffs"
}
}
[3]=>
array(7) {
["title_en"]=>
string(100) "Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing"
["snippet_en"]=>
string(288) "Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away| Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal"
["url"]=>
string(107) "https://www.fiercebiotech.com/biotech/novartis-may-have-bought-morphosys-it-only-had-eyes-its-bet-inhibitor"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/9cfe5fba-3338-4e41-a3bc-c11c5477751e"
["source"]=>
string(17) "fiercebiotech.com"
["publication_date"]=>
string(10) "2024-04-12"
["categories"]=>
array(0) {
}
}
[4]=>
array(7) {
["title_en"]=>
string(63) "Promising results and stream of clinical announcements in sight"
["snippet_en"]=>
string(269) "The biotech controlled, like bioMérieux (p. 9), by the Mérieux family has been managed since the summer by Alessandro Riva, an experienced oncologist who participated in the integration of innovations in immuno-oncology (Cart-T) in the Novartis and Gilead portfolios."
["url"]=>
string(129) "https://investir.lesechos.fr/conseils-boursiers/conseils-actions/resultats-prometteurs-et-flot-dannonces-cliniques-en-vue-2088720"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fd4d6021-bab8-40ed-a2b5-2007263d1d34"
["source"]=>
string(11) "lesechos.fr"
["publication_date"]=>
string(10) "2024-04-12"
["categories"]=>
array(0) {
}
}
[5]=>
array(7) {
["title_en"]=>
string(68) "Dividend paradise Switzerland: These shareholders are cashing in now"
["snippet_en"]=>
string(108) "Now is dividend season. Roche, Novartis and Nestlé alone pay out eight billion francs to shareholders each."
["url"]=>
string(100) "https://www.20min.ch/story/dividenden-paradies-schweiz-diese-aktionaere-kassieren-jetzt-ab-103082741"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/27b1c7b6-c2f0-4ba7-bb4a-259fa991ccfd"
["source"]=>
string(8) "20min.ch"
["publication_date"]=>
string(10) "2024-04-12"
["categories"]=>
array(2) {
[0]=>
string(21) "Shareholders Feedback"
[1]=>
string(18) "Board Compensation"
}
}
[6]=>
array(7) {
["title_en"]=>
string(59) "Bitter at Tsipras: Was the Novartis case simply mishandled?"
["snippet_en"]=>
string(80) "sofokleous10.gr Bitter towards Tsipras: Was the Novartis case simply mishandled?"
["url"]=>
string(230) "https://sofokleous10.gr/2024/04/12/%CF%80%CE%B9%CE%BA%CF%81%CE%B1%CE%BC%CE%BC%CE%AD%CE%BD%CE%BF%CF%82-%CF%83%CE%B5-%CF%84%CF%83%CE%AF%CF%80%CF%81%CE%B1-%CE%B7-%CF%85%CF%80%CF%8C%CE%B8%CE%B5%CF%83%CE%B7-novartis-%CE%AE%CF%84%CE%B1/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/791d4d61-bb1d-40b3-892f-9918d6fe4a1c"
["source"]=>
string(15) "sofokleous10.gr"
["publication_date"]=>
string(10) "2024-04-12"
["categories"]=>
array(0) {
}
}
[7]=>
array(7) {
["title_en"]=>
string(136) "Continuing to Work Beyond Retirement: How AHV is Helping Individuals Balance Their Personal Needs and Financial Futures". - News Exactly"
["snippet_en"]=>
string(158) "As the shortage of skilled workers continues to grow, many individuals are considering ways to improve their pension plans. Three professionals share why they"
["url"]=>
string(143) "https://newsexactly.com/continuing-to-work-beyond-retirement-how-ahv-is-helping-individuals-balance-their-personal-needs-and-financial-futures/"
["image_url"]=>
NULL
["source"]=>
string(15) "newsexactly.com"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(1) {
[0]=>
string(14) "Staff Shortage"
}
}
[8]=>
array(7) {
["title_en"]=>
string(127) "EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis"
["snippet_en"]=>
string(127) "EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis"
["url"]=>
string(170) "https://www.sharewise.com/de/news_articles/EQSNews_MorphoSys_Management_Board_and_Supervisory_Board_Recommend_Shareholders_Accept_Public_Tak_Morphosys_eqsen_20240411_1238"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/7ba6842e-7ec6-426f-87d8-6ea15c611b21"
["source"]=>
string(13) "sharewise.com"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(5) {
[0]=>
string(21) "Shareholders Feedback"
[1]=>
string(6) "Merger"
[2]=>
string(20) "Corporate Governance"
[3]=>
string(12) "Board Change"
[4]=>
string(11) "Acquisition"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(526)
}
[1]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(447)
}
[2]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(421)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(309)
}
[4]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(300)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(239)
}
[6]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(238)
}
[7]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(229)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(190)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(189)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(179)
}
[11]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(161)
}
[12]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(160)
}
[13]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(159)
}
[14]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(140)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(135)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(130)
}
[17]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(124)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(118)
}
[19]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(113)
}
[20]=>
array(2) {
["name"]=>
string(8) "spin-off"
["count"]=>
int(111)
}
[21]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(109)
}
[22]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(95)
}
[23]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(94)
}
[24]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(85)
}
[25]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(83)
}
[26]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(81)
}
[27]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(80)
}
[28]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(77)
}
[29]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(74)
}
}
}
a26d9-us-avexis-inc
Novartis Gene Therapies, Inc.
Location
Illinois
Founded
2010-02-28
Website
https://www.novartis.com
Articles
7769 Articles
Category
Pharmaceutical Preparations
Description
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP
Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away| Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal
The biotech controlled, like bioMérieux (p. 9), by the Mérieux family has been managed since the summer by Alessandro Riva, an experienced oncologist who participated in the integration of innovations in immuno-oncology (Cart-T) in the Novartis and Gilead portfolios.
As the shortage of skilled workers continues to grow, many individuals are considering ways to improve their pension plans. Three professionals share why they
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
